Human-induced pluripotent stem cell models of inherited cardiomyopathies

Current Opinion in Cardiology

Volumn 29, Issue 3, 2014, Pages 214-219

  Karakikes, Ioannis ^a,b   Termglinchan, Vittavat ^a,b,c   Wu, Joseph C ^a,b,c,d  

^a STANFORD UNIVERSITY   (United States)

^b Division of Cardiology   (United States)

^c Department of Radiology ^*  (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

arrhythmogenic right ventricular cardiomyopathy; dilated cardiomyopathy; hypertrophic cardiomyopathy,induced pluripotent stem cells; inherited cardiomyopathy

Indexed keywords

CARDIOMYOPATHY; CONGESTIVE CARDIOMYOPATHY; FAMILIAL DISEASE; FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; HEART MUSCLE CELL; HEART PROARRHYTHMIA; HEART RIGHT VENTRICLE DYSPLASIA; HUMAN; MUTATION; PATHOGENESIS; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; RESTRICTIVE CARDIOMYOPATHY; REVIEW; VENTRICULAR NONCOMPACTION; ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA; BIOLOGICAL MODEL; CARDIOMYOPATHY, DILATED; CARDIOMYOPATHY, HYPERTROPHIC, FAMILIAL; DRUG DEVELOPMENT; DRUG EFFECTS; GENETIC ASSOCIATION; IN VITRO STUDY; PATHOLOGY; PROCEDURES; TRENDS;

ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA; CARDIOMYOPATHY, DILATED; CARDIOMYOPATHY, HYPERTROPHIC, FAMILIAL; DRUG DISCOVERY; GENOME-WIDE ASSOCIATION STUDY; HUMANS; IN VITRO TECHNIQUES; INDUCED PLURIPOTENT STEM CELLS; MODELS, CARDIOVASCULAR; MYOCYTES, CARDIAC;

EID: 84899480082     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0000000000000049     Document Type: Review

References (24)

1. Watkins H, Ashrafian H, Redwood C. Inherited cardiomyopathies. N Engl J Med 2011; 364:1643-1656.
2. Hershberger RE, Cowan J, Morales A, et al. Progress with genetic cardiomyopathies: screening, counseling, and testing in dilated, hypertrophic, and arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Heart Fail 2009; 2:253-261.
3. Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science 1998; 282:1145-1147.
4. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131:861-872.
5. Frey N, Luedde M, Katus HA. Mechanisms of disease: hypertrophic cardiomyopathy. Nat Rev Cardiol 2012; 9:91-100.
6. Lan F, Lee AS, Liang P, et al. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell 2013; 12:101-113.
7. Becker JR, Deo RC, Werdich AA, et al. Human cardiomyopathy mutations induce myocyte hyperplasia and activate hypertrophic pathways during cardiogenesis in Zebrafish. Dis Model Mech 2011; 4:400-410.
8. Geisterfer-Lowrance AA, Christe M, Conner DA, et al. A mouse model of familial hypertrophic cardiomyopathy. Science 1996; 272:731-734.
9. Hershberger RE, Hedges DJ, Morales A. Dilated cardiomyopathy: the complexity of a diverse genetic architecture. Nat Rev Cardiol 2013; 10:531-547.
10. Sun N, Yazawa M, Liu J, et al. Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci Transl Med 2012; 4:130ra47.
11. Tse HF, Ho JC, Choi SW, et al. Patient-specific induced-pluripotent stem cells-derived cardiomyocytes recapitulate the pathogenic phenotypes of dilated cardiomyopathy due to a novel des mutation identified by whole exome sequencing. Hum Mol Genet 2013; 22:1395-1403.
12. Siu CW, Lee YK, Ho JC, et al. Modeling of lamin a/C mutation premature cardiac aging using patient-specific induced pluripotent stem cells. Aging (Albany NY) 2012; 4:803-822.
13. Awad MM, Calkins H, Judge DP. Mechanisms of disease: molecular genetics of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Nat Clin Pract Cardiovasc Med 2008; 5:258-267.
14. Kim C, Wong J, Wen J, et al. Studying arrhythmogenic right ventricular dysplasia with patient-specific IPSCs. Nature 2013; 494:105-110.
15. Ma D, Wei H, Lu J, et al. Generation of patient-specific induced pluripotent stem cell-derived cardiomyocytes as a cellular model of arrhythmogenic right ventricular cardiomyopathy. Eur Heart J 2013; 34:1122-1133.
16. Caspi O, Huber I, Gepstein A, et al. Modeling of arrhythmogenic right ventricular cardiomyopathy with human induced pluripotent stem cells. Circ Cardiovasc Genet 2013; 6:557-568.
17. Mordwinkin NM, Lee AS, Wu JC. Patient-specific stem cells and cardiovascular drug discovery. JAMA 2013; 310:2039-2040.
18. Sauer AJ, Newton-Cheh C. Clinical and genetic determinants of torsade de pointes risk. Circulation 2012; 125:1684-1694.
19. Burridge PW, Keller G, Gold JD, et al. Production of de novo cardiomyocytes: human pluripotent stem cell differentiation and direct reprogramming. Cell Stem Cell 2012; 10:16-28.
20. Liang P, Lan F, Lee AS, et al. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity. Circulation 2013; 127:1677-1691.
21. Braam SR, Tertoolen L, Casini S, et al. Repolarization reserve determines drug responses in human pluripotent stem cell derived cardiomyocytes. Stem Cell Res 2013; 10:48-56.
22. Navarrete EG, Liang P, Lan F, et al. Screening drug-induced arrhythmia events using human induced pluripotent stem cell-derived cardiomyocytes and lowimpedance microelectrode arrays. Circulation 2013; 128 (11 Suppl 1):S3-S13.
23. Karakikes I, Senyei GD, Hansen J, et al. Small molecule-mediated directed differentiation of human embryonic stem cells toward ventricular cardiomyocytes. Stem Cells Transl Med 2013; 3:18-31.
24. Merkle FT, Eggan K. Modeling human disease with pluripotent stem cells: from genome association to function. Cell Stem Cell 2013; 12:656-668.